News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EuroPCR 2022 Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities Caitlin E. Cox May 25, 2022
News Conference News EAS 2022 Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level Michael O'Riordan May 24, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Conference News ACC 2022 PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI Todd Neale April 03, 2022
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer Michael O'Riordan August 30, 2021
News Conference News EAS 2021 Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI Michael O'Riordan June 07, 2021
News Conference News EAS 2021 Lp(a) Not Associated With Ongoing Aortic Valve Calcification Michael O'Riordan June 04, 2021